FDA panel backs Takeda’s CMV drug for transplant patientsTakeda is closing on a first FDA approval in the treatment of refractory cytomegalovirus (CMV) infections in organ Share XFDA panel backs Takeda’s CMV drug for transplant patientshttps://pharmaphorum.com/news/fda-panel-backs-takedas-cmv-drug-for-transplant-patients/
